A nticoagulants are used to prevent cerebrovascular events in patients with atrial fibrillation (AF). Previous studies reported that warfarin reduces the risk of stroke by 64% compared with placebo. 1 Non-vitamin K oral anticoagulants (NOACs) have been used clinically in recent years to prevent cerebrovascular events in patients with nonvalvular AF. Importantly, accumulating clinical and experimental evidence has proved that NOACs, such as dabigatoran, 2 apixaban, 3 rivaroxaban, 4 and edoxaban 5 in addition to warfarin, can reduce the likelihood of cerebrovascular events in patients with nonvalvular AF. In fact, a meta-analysis of randomized clinical trials demonstrated that NOACs had a favorable risk-benefit profile, with significant reductions in stroke, intracranial hemorrhage, and mortality and with risk of major bleeding similar to warfarin, although with increased chance of gastrointestinal bleeding. 6 NOACs are innovative drugs that solve complex patient management issues such as frequent blood sampling, dietary restriction, or drug interactions, which were problematic in the warfarin-only era. There is, however, no definitive tool to monitor the anticoagulant effects of NOACs, although some patients have bleeding complications related to exceedingly high blood concentrations of NOACs. 7, 8 Routine tests, such as prothrombin time international normalized ratio (PT-INR) and activated partial thromboplastin time (APTT), could be problematic for monitoring the anticoagulant effects of NOACs because each NOAC has a different characteristic chemical structure and a different pharmacokinetic profile (eg, plasma half-life and tissue penetration rate). 9 The T-TAS "Total Thrombus-formation Analysis System" (Fujimori Kogyo Co Ltd), 10 ,11 a microchip-based flow chamber system that can evaluate whole-blood thrombogenicity, was developed as an easy-to-use system for quantitative analysis of thrombus formation. Recently, we demonstrated that T-TAS might be a useful tool in monitoring the anticoagulant effects of edoxaban, a NOAC. 12 The aim of the present study was to evaluate the utility of T-TAS in monitoring the efficacy of warfarin and NOACs on thrombus formation and to predict the respective risk of bleeding complications in AF patients undergoing radiofrequency catheter ablation (CA).
Methods Study Population
This retrospective and observational study enrolled 148 consecutive AF patients undergoing CA at Kumamoto Representative microscopic images of thrombus formation under flow condition in AR in warfarin-treated (A) and NOACs-treated (B) groups. The time point of 0 minutes indicates initiation of measurements. C, Representative flow pressure changes under flow condition in AR. Warfarin (CA) and warfarin (1 month) represent pressure time curves of AR 10 in a warfarin-treated patient at the time of CA and at 30 days after CA, respectively. NOAC (CA) and NOAC (1 month) represent pressure time curves of AR in a NOAC-treated patient at the time of CA and at 30 days after CA, respectively. AR 10 -AUC 30 indicates area under the curve for the first 30 minutes for the atheroma chip tested at flow rate of 10 lL/min; CA, catheter ablation; NOACs, non-vitamin K oral anticoagulants; PL 24 -AUC 10 , area under the curve for the first 10 minutes for the platelet chip tested at flow rate of 24 lL/min.
University Hospital between September 2013 and August 2015. We excluded patients with cancer (n=4) and inflammatory diseases (n=1) and patients who refused participation (n=15). The remaining 128 paroxysmal/persistent AF patients were divided into 2 groups: patients treated with warfarin (n=30) and those treated with NOACs (n=98) (Figure 1 ). All procedures were conducted in accordance with the Declaration of Helsinki and its amendments. The study protocol was approved by the human ethics committee of Kumamoto University, and written informed consent was obtained from each patient or the patient's family. 
CA for Patients With AF

Periprocedural Anticoagulation Regimen and Collection of Blood Samples
Dabigatran, rivaroxaban, and apixaban were withheld in the morning the day before CA and were bridged with unfractionated heparin until 6 hours before CA. Warfarin was given in the evening once daily, interrupted 4 days before CA, and bridged with unfractionated heparin until 6 hours before CA. All NOACs were restarted the next morning after CA. Warfarin was restarted the next evening after CA and was bridged with unfractionated heparin from the next morning after CA until target PT-INR of 1.6 to 2.6. Blood samples were obtained on the day of CA (anticoagulant-free point) and at 3 days (before [trough] taking medication) and 30 days (trough) after CA. Blood samples were collected, as described in detail previously. 13 Briefly, blood samples were collected from the antecubital vein with a 21-gauge butterfly needle into the following tubes: a hirudin-containing blood sampling tube (MP0600 [Verum Diagnostia]; final concentration of hirudin 25 lg/mL), blood collection tubes (VP-CA050K70, Venoject II; Terumo), and a syringe containing 0.11 mL of 3.8% sodium citrate solution. Each sample was immediately centrifuged at 1800g for 10 minutes at room temperature, and plasma was collected for biochemical analysis. Prothrombin time and APTT were measured using commercially available thromboplastin reagents (Coagupia PT-N for prothrombin time; Coagupia APTT-N for APTT; Sekisui Medical Co), according to the protocol supplied by the manufacturer.
Measurement of Thrombogenicity by T-TAS
T-TAS is an automated microchip-based flow chamber system developed for easy and quick assessment of platelet thrombus formation under flow conditions. 10, 13, 14 We have already reported details of T-TAS, including appearance and components, and established the validity of the method with NOAC use. 12 In brief, this system analyzes different thrombusformation processes with a simple procedure using 2 microchips with different thrombogenic surfaces. One chip, the platelet chip (PL), is coated with type I collagen. Inside the microchip, platelets adhere and aggregate on the surface of the collagen, and microchip capillaries are occluded. The other chip, the atheroma chip (AR), is coated with type I collagen plus tissue thromboplastin. Inside the microchip, activation of the platelets and the coagulation system is triggered simultaneously by collagen and tissue thromboplastin, respectively. The process of thrombus formation inside the 2 chips was analyzed by monitoring the flow pressure change. The area under the curve (AUC) for flow pressure was computed to assess platelet thrombogenicity inside the microchips. AUC for the first 10 minutes for the PL tested at flow rate of 24 lL/min is described as PL 24 -AUC 10 , and AUC for the first 30 minutes for the AR tested at flow rate of 10 lL/min is described as AR 10 -AUC 30 .
Efficacy and Safety End Points
The efficacy outcome included stroke or systemic embolism. Periprocedural bleeding events were defined as bleeding complications within 30 days after CA. We defined major and minor bleeding according to the 2012 Heart Rhythm Society, European Heart Rhythm Association, and European Cardiac Arrhythmia Society expert consensus statement on catheter and surgical ablation of AF. 15 Major bleeding was defined as severe bleeding requiring blood transfusion or hematoma requiring surgical intervention. Small hematomas and pericardial effusion that did not require any intervention were considered minor bleeding complications. Anticoagulant therapy was immediately withdrawn in patients who developed major bleeding, and their data were excluded from analysis.
Statistical Analysis
Continuous variables with normal distribution were expressed as meanAESD, and categorical variables were expressed as frequencies and percentages, whereas those with skewed distribution were expressed as median values with interquartile range. Continuous variables were analyzed by the unpaired or paired t test for data with normal distribution, as appropriate, and the Mann-Whitney U test or Wilcoxon signed rank test for data with skewed distribution, as appropriate. Age, sex, history of disease, blood counts, blood biochemical and coagulation parameters, and other significant parameters in simple logistic analysis were entered into multiple logistic regression analysis to determine their association with bleeding events using the forced entry method, and the Hosmer-Lemeshow goodness-offit statistic was calculated. A receiver operating characteristic curve was generated, and the AUC and its 95% CI were calculated to assess the ability of T-TAS parameters, prothrombin time, and APTT at the point of CA to predict bleeding events. A 2-tailed P value of <0.05 denoted the presence of a statistically significant difference. All statistical analyses were performed by using the SPSS software version 22 (IBM Corp).
Results
Baseline Patient Characteristics Table 1 shows the baseline characteristics of patients treated with warfarin (n=30) and NOACs (n=98). The NOACs group comprised patients treated with dabigatran (n=21), rivaroxaban (n=52), and apixaban (n=25). There were no significant differences in baseline characteristics among the warfarin and
NOACs groups except for a higher rate of patients with a HAS-BLED score of 0 and use of antiarrhythmic drugs in the NOACs group. Figure 1A and 1B show representative microscopic images of thrombus formation under flow condition in AR in warfarinand NOACs-treated groups. Total thrombus formation (indicated in white) was suppressed in both warfarin-and NOACs-treated groups ( Figure 1A and 1B) . Figure 1C shows representative flow pressure changes under flow conditions in AR. The pressure time curves of AR 10 in the warfarin and NOAC groups shifted to the right, indicating the suppression of thrombus formation 30 days after CA in both groups. Table 2 and Figure 2 show serial changes in T-TAS parameters (AR 10 -AUC 30 and PL 24 -AUC 10 ), PT-INR, and APTT in patients treated with warfarin and NOACs. There were no significant differences in baseline AR 10 -AUC 30 , PL 24 -AUC 10 , PT-INR, and APTT levels between the 2 groups. In each group, the AR 10 -AUC 30 levels at 3 and 30 days after CA were significantly lower than those at the day of CA; however, there were no significant differences in PL 24 -AUC 10 levels among the different time points. The PT-INR and APTT levels were significantly higher at 3 and 30 days after CA than the day of CA in each group. Table 3 shows serial changes in T-TAS parameters, PT-INR, and APTT according to the type of NOACs (dabigatran, rivaroxaban, and apixaban). There were no significant differences in baseline AR 10 -AUC 30 , PL 24 -AUC 10 , PT-INR, and APTT levels among the 3 NOACs groups except for a higher APTT level in the dabigatran group compared with the rivaroxaban group. In all 3 subgroups, AR 10 -AUC 30 levels were significantly lower at 3 and 30 days after CA than those at the day of CA, although the AR 10 -AUC 30 levels at each sampling point were identical among the 3 NOACs groups. with aspirin. None of the patients was treated with other antiplatelet drugs apart from aspirin. Furthermore, there were no significant differences in procedure time, activated clotting time levels at the end of CA, and total dose of heparin during CA between the groups with and without periprocedural bleeding events. Table 5 and Figure 3 show the levels of T-TAS parameters (AR 10 -AUC 30 and PL 24 -AUC 10 ), PT-INR, and APTT in patients with and without periprocedural bleeding events. The AR 10 -AUC 30 and PL 24 -AUC 10 levels were significantly lower in the group with periprocedural bleeding events than the group without such events at the day of and 3 days after CA. In contrast, PT-INR and APTT levels were identical between the groups with and without periprocedural bleeding events at the day of and 3 days after CA.
Effects of Warfarin and NOACs on T-TAS Parameters, PT-INR, and APTT
Effects of Anticoagulants on
Predictors of Periprocedural Bleeding Events
We also analyzed the predictors of periprocedural bleeding events in AF patients who underwent CA. Simple logistic regression analysis demonstrated that platelet count and AR 10 -AUC 30 level at the day of CA correlated with periprocedural bleeding events (Table 6 ). There were weak positive correlations of AR 10 -AUC 30 with hemoglobin levels (r=0.244, P=0.006), platelet count (r=0.325, P=0.006), use of NOACs (r=0.174, P=0.049), PL 24 -AUC 10 levels (r=0.368, P<0.001), and PT-INR (r=0.226, P=0.012). Multiple logistic regression analyses using 3 forced inclusion models that included various clinical parameters such as platelet count, AR 10 -AUC 30 , PT-INR, and APTT levels identified AR 10 -AUC 30 level at the day of CA as a significant predictor of periprocedural bleeding events in all 3 models (Table 7) , with a HosmerLemeshow goodness-of-fit chi-square of 2.195 (P=0.33) in model 1), 0.608 (P=0.74) in model 2, and 0.315 (P=0.854) in model 3.
Receiver Operating Characteristic Analysis for Periprocedural Bleeding Events and T-TAS Parameters, PT-INR, and APTT
Receiver operating characteristic curves were constructed to assess the ability of T-TAS parameters, PT-INR, and APTT at the point of CA and 3 days after CA to predict periprocedural bleeding events. The AUC of AR 10 -AUC 30 for detection of periprocedural bleeding events was 0.859 (95% CI 0.766-0.951; P<0.001) at the point of CA ( Figure 4A ) and 0.759 (95% CI 0.657-0.862; P<0.001) at 3 days after CA (Figure 4B) . In contrast, the AUCs of PL 24 -AUC 10 , PT-INR, and APTT for the detection of periprocedural bleeding events were 0.657 (95% CI 0.513-0.802; P=0.02), 0.601 (95% CI 0.464-0.738; P=0.15), and 0.592 (95% CI 0.463-0.720; P=0. 20) , respectively, at the point of CA and 0.705 (95% CI 0.577-0.833; P=0.007), 0.547 (95% CI 0.402-0.692; P=0.54), and 0.547 (95% CI 0.414-0.680; P=0.54), respectively, at 3 days after CA. Using the cutoff value for AR 10 -AUC 30 at the day of CA (1648) and 3 days after CA (1582), the sensitivity and specificity for detection of a bleeding event were 71% and 90%, respectively, at the point of CA and 89% and 57%, respectively, at 3 days after CA. 10 , area under the curve for the first 10 minutes for the platelet chip tested at flow rate of 24 lL/min; PPI, proton pump inhibitor. *Data of this parameter was lower than the median value at the point of CA.
Discussion
The main feature of the present study was assessment of whole blood thrombogenicity using T-TAS in patients treated with anticoagulants who underwent CA for AF. The main findings were as follows: (1) patients who underwent CA for AF. These results indicate that T-TAS is a potentially suitable monitoring system for the assessment of the anticoagulant effects in AF patients treated with NOACs. In the present study, major and all bleeding events were observed in 2.4% and 16.4%, respectively, of the total study population. These rates are almost identical to those described in previous studies after CA for AF of 1.2% to 3.5% and 5% to 13.9%. [20] [21] [22] T-TAS, the microchip-based flow chamber apparatus used for evaluation of the extent of thrombus formation, is novel and easy to use for quantitatively monitoring the levels of thrombogenesis under a whole blood flow state. In the present study, we used PL, which can assess thrombogenicity associated with platelets, and AR, which can assess thrombogenicity under the condition of platelets and coagulationfibrinolysis factors. In this study, AR 10 -AUC 30 levels decreased significantly after anticoagulation with warfarin or NOACs, whereas PL 24 -AUC 10 was not suitable for assessment of the effects of anticoagulant therapy. Furthermore, the AR 10 -AUC 30 levels at all sampling points were identical among the 3 NOACs (dabigatran, rivaroxaban, and apixaban) subgroups. Based on these findings, we believe that AR (AR 10 -AUC 30 levels) is potentially suitable for monitoring the effects of any anticoagulant therapy (eg, warfarin, heparin, and NOACs), whereas PL (PL 24 -AUC 10 ) is perhaps useful for clinical studies monitoring antiplatelet therapy, including aspirin, clopidogrel, or prasugrel in patients with coronary artery disease.
It was demonstrated previously that inhibition of factors VIII and IX effectively reduced the growth of thrombi in AR under lower shear conditions (110 s À1 ), whereas no significant change was observed under pathological high-shear conditions (1100 s À1 ). 23 Although lower shear conditions (ie, ≤110 s À1 ) may be suitable for specific assessment of thrombogenicity in the left atrium, in which the coagulation system plays a predominant role, it is anticipated that the T-TAS parameter AR 10 -AUC 30 (with a low-to midshear rate of 600 s À1 ), which simulates the shear conditions at small veins and large arteries, can also be used to evaluate thrombus formation in the left atrium. We previously demonstrated the usefulness of AR 10 -AUC 30 in distinguishing the pharmacological effects of edoxaban, a NOAC, in patients undergoing total knee arthroplasty. 12 The present data also showed low AR 10 -AUC 30 levels at 3 and 30 days post-CA compared with those on the day of CA, indicating that anticoagulant therapy with warfarin or NOACs significantly decreased AR 10 -AUC 30 levels. Based on these findings, we believe that AR 10 -AUC 30 levels measured by T-TAS could be useful for monitoring the efficacy and safety of warfarin and NOACs in AF patients. Further prospective large-population studies are needed to establish the relationship between AR 10 -AUC 30 levels and future thromboembolic events.
The present study has several limitations. First, this singlecenter observational study included a relatively small number of patients; however, the strength of the study is the enrollment of consecutive patients. In this sense, the study population represents real-world patients with AF referred for CA. Second, we did not follow the serial changes in T-TAS parameters and coagulant markers in the non-AF control patients. Third, there was no significant difference in the frequency of periprocedural bleeding complications between the warfarin and NOACs groups; this finding is probably related to the small sample size. Further large-population studies are needed to examine the relationship between AR 10 -AUC 30 measured by T-TAS and the rates of periprocedural bleeding complications in patients treated with warfarin and NOACs.
In conclusion, our results demonstrated that AR 10 -AUC 30 level measured by T-TAS was an independent and significant tool for assessment of the efficacy of warfarin and NOACs in AF patients who underwent CA and that this marker could be a useful predictor of periprocedural bleeding events in such patients.
